期刊文献+

LC-MS/MS法测定人全血中他克莫司的浓度及其在生物等效性试验中的应用 被引量:7

LC-MS/MS determination of tacrolimus in human blood and application in its bioequivalence study
原文传递
导出
摘要 目的:建立高效液相色谱-质谱联用法测定人全血中他克莫司浓度。方法:选用Shim-pack VP-ODS柱色谱柱(5μm,150 mm×4.6 mm),以乙腈-10 mmol·L-1醋酸铵为流动相,采用梯度洗脱进行分离,流速:0.8 mL·min-1;柱温:25℃;进样量:20μL。样品用乙腈进行蛋白沉淀后进样,选用3200QTRAP型质谱仪的多重反应监测(MRM)扫描方式进行检测。结果:他克莫司的线性范围为0.1~25.0 ng·mL-1,定量下限和最低检测限分别为0.1 ng·mL-1和0.05 ng·mL-1。准确度与精密度结果显示方法日间、日内变异均小于15%,相对偏差为-6.5%~4.3%,方法提取回收率均接近100.0%,稳定性较好。结论:本研究所建立的方法快速、灵敏,专属性强,重复性好,适用于他克莫司人体生物等效性试验。 Objective: To develop an LC - MS/MS method for the determination of the tacrolimus (FKS06) in hu- man whole blood. Method: Tacrolimus and the internal standard were extracted from whole blood by acetonitrile which was used as deproteinated solvent,and separated on a Shim -pack VP -ODS column (5 μm, 150 mm × 4. 6 mm) maintained at 25℃ with acetonitrile and 10 mmol · L^-1 ammonium acetate as mobile phase by gradient elution. The flow rate was 0. 8 mL· min^-1 and 20 μL aliquot of residues were injected into the LC - MS/MS system. Detection was carried out by multiple reaction monitoring on a 3200QTRAP LC - MS/MS system. Results:The as- say was linear over the range 0. 1-25.0 ng·mL^-1 with a limit of quantitation of 0. 1 ng · mL^-1 and a limit of detection of 0.05 ng·mL^-1. Intra -and inter - day precision were less than 15 %, respectively. The relative deviation was from - 6. 5% to 4. 3%. The recoveries of tacrolimus were almost 100. 0% and stabilities were good. Conclusion :The method is a rapid, sensitive, selective and reliable for the determination of tacrolimus in human whole blood. The assay is applied to a bioequivalence study of tacrolimus to healthy volunteers.
出处 《药物分析杂志》 CAS CSCD 北大核心 2009年第2期237-242,共6页 Chinese Journal of Pharmaceutical Analysis
关键词 高效液相色谱-质谱联用法 他克莫司 LC - MS/MS tacrolimus
  • 相关文献

参考文献43

  • 1Chand DH, Southerland SM, Cunningham RJ. Tacrolimus : the good, the bad,and the ugly. Pediatr Transplant,2001,5( 1 ) :32
  • 2Jain A, Venkataramanan R, Sharma R,et al. Pharmacokinetics of tacroliraus in living donor liver transplant and deceased donor liver transplant recipients. Transplantation ,2008,85 (4) :554
  • 3Herna. ndez D,Alvarez A,Torres A, et al. Cardiovascular risk profile in nondiabetic renal transplant patients:cyclosporine versus tacrolimus. Transplant Proc,2003,35 ( 5 ) : 1727
  • 4Park SI, Felipe CR, Pinheiro - Machado PG, et al. Circadian and time- dependent variability in tacrolimus pharmacokinetics. Fundam Clin Pharmacol,2007,21 ( 2 ) : 191
  • 5Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacoklnetics in renal transplant candidates: guidelines from an experimental study. Ant J Transplant .2006,6( 11 ) :2706
  • 6Staatz CE, Tett SE. Pharmacokinetic considerations relating to tacrolimus dosing in the ehlerly. Drugs Aging ,2005,22 (7) :541
  • 7Park K,Kim YS,Kwon KI, et al. A randomized,open -label,two - period,crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults. Clin Ther,2007,29( 1 ) :154
  • 8Sam WJ,Tham LS, Holmes M J, et al. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. Clin Pharmacokinet ,2006,45 ( 1 ) :59
  • 9Schubert M,Venkataramanan R, Holt DW, et al. Pharmaeokineties of sirolimus and taerolimus in pediatric transplant patients. Ant J Transplant, 2004,4 ( 5 ) :767
  • 10Kyles AE, Gregory CR, Craigmill AL, et al. Pharmacokinetics of tacrolimus after muhidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants. Am J Vet Res,2003 ,64( 7 ) :926

同被引文献555

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部